"An exciting finding was when we tried to treat the obese mice with colon inflammation by lowering their inflammation, it actually stopped the ERK pathway in the liver from activating," explains Imai.

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.